CBP/p300双抑制剂对cBAF缺陷型癌症中KREMEN2去抑制的疗效
Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers.
作者信息
Sasaki Mariko, Kato Daiki, Yoshida Hiroshi, Shimizu Takafumi, Ogiwara Hideaki
机构信息
Division of Cancer Therapeutics, National Cancer Center Research Institute, Tokyo, Japan.
Cancer Research Unit, Sumitomo Pharma Co., Ltd, Osaka, Japan.
出版信息
Cancer Res Commun. 2025 Jan 1;5(1):24-38. doi: 10.1158/2767-9764.CRC-24-0484.
In this study, we clarified that the cBAF subcomplex is deficient in the SWI/SNF complex, resulting in dependency on the CBP/p300 paralog pair. Simultaneous inhibitors of the CBP/p300 paralog pair show promise for cBAF-deficient lung cancer, as well as rare cancers such as malignant rhabdoid tumors, epithelioid sarcomas, and synovial sarcomas.
在本研究中，我们阐明了cBAF亚复合物在SWI/SNF复合物中存在缺陷，导致对CBP/p300旁系同源物对的依赖性。CBP/p300旁系同源物对的同时抑制剂对cBAF缺陷型肺癌以及恶性横纹肌样肿瘤、上皮样肉瘤和滑膜肉瘤等罕见癌症显示出前景。
Zotero 插件